{"DataElement":{"publicId":"4986326","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T Stage","preferredDefinition":"Extent of the primary duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.","longName":"4985469v1.0:4985929v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"4985469","version":"1","preferredName":"Digestive System Neuroendocrine Neoplasm Pathologic T Stage","preferredDefinition":"A neoplasm with neuroendocrine differentiation arising from the digestive system.  It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas)._Caused by or altered by or manifesting disease or pathology._One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"4985461v1.0:2207099v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"4985461","version":"1","preferredName":"Digestive System Neuroendocrine Neoplasm","preferredDefinition":"A neoplasm with neuroendocrine differentiation arising from the digestive system.  It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).","longName":"C27721","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestive System Neuroendocrine Neoplasm","conceptCode":"C27721","definition":"A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2B1F3A-D181-5724-E050-BB89AD435649","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-25","modifiedBy":"ONEDATA","dateModified":"2015-08-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207099","version":"1","preferredName":"Pathologic T Stage","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C25610:C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1838-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2B5679-D746-666E-E050-BB89AD4303B8","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created per request by COG for their APEC14B1 study in Rave. mc 8/25/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4985929","version":"1","preferredName":"Digestive System Neuroendocrine Neoplasm American Joint Committee on Cancer (AJCC) Edition 7 T Stage","preferredDefinition":"A neoplasm with neuroendocrine differentiation arising from the digestive system.  It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas)._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"4985929v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T0","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT0 TNM Finding v7","ValueMeaning":{"publicId":"4985931","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT0 TNM Finding v7","longName":"4985931","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT0 TNM Finding v7","conceptCode":"C90084","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F978-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-F991-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"},{"value":"T1","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT1 TNM Finding v7","ValueMeaning":{"publicId":"4985933","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT1 TNM Finding v7","longName":"4985933","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading lamina propria or submucosa and is 1 cm or less in size (small intestinal tumors); for ampullary tumors: tumor 1 cm or less. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT1 TNM Finding v7","conceptCode":"C90085","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading lamina propria or submucosa and is 1 cm or less in size (small intestinal tumors); for ampullary tumors: tumor 1 cm or less. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F99E-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-F9B7-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"},{"value":"T2","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT2 TNM Finding v7","ValueMeaning":{"publicId":"4985935","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT2 TNM Finding v7","longName":"4985935","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading muscularis propria or is more than 1 cm in size (small intestinal tumors); for ampullary tumors: tumor more than 1 cm. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT2 TNM Finding v7","conceptCode":"C90086","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading muscularis propria or is more than 1 cm in size (small intestinal tumors); for ampullary tumors: tumor more than 1 cm. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F9C4-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-F9DD-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"},{"value":"T3","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT3 TNM Finding v7","ValueMeaning":{"publicId":"4985937","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT3 TNM Finding v7","longName":"4985937","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invading pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT3 TNM Finding v7","conceptCode":"C90087","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invading pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F9EA-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-FA03-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"},{"value":"T4","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT4 TNM Finding v7","ValueMeaning":{"publicId":"4985939","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT4 TNM Finding v7","longName":"4985939","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading visceral peritoneum (serosa) or invading other organs. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT4 TNM Finding v7","conceptCode":"C90090","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading visceral peritoneum (serosa) or invading other organs. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-FA10-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-FA29-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"},{"value":"TX","valueDescription":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pTX TNM Finding v7","ValueMeaning":{"publicId":"4985941","version":"1","preferredName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pTX TNM Finding v7","longName":"4985941","preferredDefinition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pTX TNM Finding v7","conceptCode":"C90083","definition":"Duodenum/ampulla/jejunum/ileum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-FA36-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E3891DB-FA4F-17E5-E050-BB89AD433150","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4985928","version":"1","preferredName":"Digestive System Neuroendocrine Neoplasm American Joint Committee on Cancer T Stage Stage","preferredDefinition":"A neoplasm with neuroendocrine differentiation arising from the digestive system.  It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C27721:C39315:C25728:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestive System Neuroendocrine Neoplasm","conceptCode":"C27721","definition":"A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F94C-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"ONEDATA","dateModified":"2015-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E3891DB-F95D-17E5-E050-BB89AD433150","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"COOPERM","dateModified":"2015-09-22","changeDescription":"Created per request by COG for their APEC14B1 study in Rave. mc 8/25/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"4985894","version":"1","longName":"Neuroendocrine","context":"NCIP"},{"publicId":"4985892","version":"1","longName":"Duodenum/Ampulla/Jejunum/Ileum","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"5777526","version":"1","longName":"Neuroendocrine ","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Pathologic T Stage","type":"Preferred Question Text","description":"Pathologic T Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"1E3B406F-4992-408D-E050-BB89AD430537","latestVersionIndicator":"Yes","beginDate":"2015-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-26","modifiedBy":"TAYLORT","dateModified":"2017-04-19","changeDescription":"Created by COG request for their APEC14B1 study in Rave. mc 8/26/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}